Similar articles

• Therapy and clinical trials: ezetimibe.

  Jialal I, Kappagoda T. Jialal I, et al. Curr Opin Lipidol. 2003 Dec;14(6):643-6. doi: 10.1097/00041433-200312000-00015. Curr Opin Lipidol. 2003. PMID: 14624143 No abstract available.
• [Ezetimibe--intestinal cholesterol absorbtion inhibitor].

  Pikto-Pietkiewicz W, Pasierski T. Pikto-Pietkiewicz W, et al. Kardiol Pol. 2006 Dec;64(12):1434-41. Kardiol Pol. 2006. PMID: 17206545 Review. Polish. No abstract available.
• Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.

  Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri EP; Ezetimibe Study Group. Kerzner B, et al. Am J Cardiol. 2003 Feb 15;91(4):418-24. doi: 10.1016/s0002-9149(02)03236-8. Am J Cardiol. 2003. PMID: 12586255 Clinical Trial.
• [On the current debate on lowering LDL cholesterol with ezetimibe].

  Breuer HW. Breuer HW. Dtsch Med Wochenschr. 2010 Nov;135(44):2201; author reply 2202. doi: 10.1055/s-0030-1267499. Epub 2010 Oct 26. Dtsch Med Wochenschr. 2010. PMID: 20979008 German. No abstract available.
• Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption.

  Bruckert E, Giral P, Tellier P. Bruckert E, et al. Circulation. 2003 Jul 1;107(25):3124-8. doi: 10.1161/01.CIR.0000072345.98581.24. Circulation. 2003. PMID: 12835406 Review. No abstract available.